September quarter revenue rises 35%, but profit slips 5%

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionResults View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.2%Reaction day

₹393.70

prior close

₹402.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-4.6% vs market

Pharmaceuticals peers, median of 156sector-0.0%-4.2% vs sector

On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-1.6

15m

-1.0

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.2+0.4-4.6-0.0-4.2

Next day

+0.3+0.0+0.3-0.7+1.0

+3.6-0.2+3.9-1.0+4.6

+1.6+0.7+0.9+0.1+1.5

+1.6+0.6+1.0+0.2+1.4

-0.6+0.5-1.1+0.0-0.6

+2.4+0.3+2.1-0.3+2.7

15d

-4.5-1.5-3.0-1.6-2.9

-9.1-6.6-2.6-5.3-3.8

+1.4-3.2+4.6-2.9+4.3

+24.0-5.2+29.1-7.4+31.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the quarter ended September 30, 2025, revenue rose 34.6% to Rs 57.56 crore from Rs 42.78 crore, while profit after tax fell 5.3% to Rs 4.54 crore. For the first half, revenue rose 31.4% to Rs 110.30 crore and profit rose 27.8% to Rs 9.21 crore. Operating cash flow was Rs 30.59 crore.

Likely market impact

Strong sales, half-year profit growth and cash flow are positive, but lower margins and a quarterly profit decline may limit near-term gains.